ArticleScientific reports2025
Chimeric virus-like particles carrying the CLEC17A carbohydrate-recognition domain significantly reduce Macrobrachium rosenbergii nodavirus infection in Sf9 cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Our previous studies demonstrated that Macrobrachium rosenbergii nodavirus (MrNV) infects and replicates in Sf9 insect cells, where fucosylated N- and O-glycans (HexNAc (Fuc)HexNAc-R or Fuc-LacdiNAc) serve as essential binding molecules for viral attachment. Additionally, we showed that the virus-like particles of the virus itself (MrNV-VLPs) were able to bind to the white-tail disease (WTD)-associated tissues and infect Sf9 cells; and these processes were significantly reduced by removing 27 amino acids from the C-terminus of the protruding (P) domain. In this study, we demonstrated that icosahedral particles could still form following the truncation of the P-domain at sites adjacent to known calcium-binding domains (CBDs) present in the S-shell domain in the MrNV capsid protein. We further showed that icosahedral particles could still form after truncation of the P-domain near calcium-binding sites in the S-domain. This generated smaller but intact particles lacking protrusions, designated V250-MrNV-VLPs. The particles with their intact S-shells enabled our complete replacement of the original MrNV capsid protein P-domains with the fucose-binding carbohydrate-recognition domain (CRD) of CLEC17A lectin (Prolectin), successfully creating CLEC17A/CRD-MrNV-VLPs. The chimeric CLEC17A/CRD-MrNV-VLPs were stable icosahedral particles with P-domains structurally distinct from both the smooth V250-MrNV-VLPs and the blade-like domains of wild-type MrNV-VLPs. Furthermore, the chimeric VLPs presented specific binding activities towards immobilized fucosylated glycoconjugates and Sf9 cell protein lysates. Notably, CLEC17A/CRD-MrNV-VLPs were able to reduce MrNV binding and infection in Sf9 cells. Therefore, this study demonstrated the potential for CLEC17A/CRD-MrNV-VLPs as particles that can effectively bind to fucosylated glycans, and their potential development as nanoparticles that can significantly reduce the level of infection by MrNV in susceptible cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.